Dr Timothy P Long, MD | |
200 N Highway 47, Marthasville, MO 63357 | |
(636) 433-5411 | |
(636) 433-2910 |
Full Name | Dr Timothy P Long |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 46 Years |
Location | 200 N Highway 47, Marthasville, Missouri |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558384214 | NPI | - | NPPES |
010121863 | Other | RAILROAD MEDICARE | |
200987253 | Medicaid | MO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | R9468 (Missouri) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mercy Clinic East Communities | 7214827922 | 491 |
News Archive
Reinforcing its reputation as a world-leading provider of automated healthcare solutions and medication adherence packaging, Omnicell UK & Ireland has launched a new generation of automated medication dispensing systems, Omnicell XT, at the forefront of technological advancement.
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
The U.S. Food and Drug Administration today approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.
In response to the current trend toward personalized medicine, the Beaumont Weight Control Center, affiliated with Beaumont Hospitals, a major Detroit-area health system, now offers individualized MicroNutrient Testing for patients.
› Verified 4 days ago
Entity Name | Mercy Clinic East Communities |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1851335228 PECOS PAC ID: 7214827922 Enrollment ID: O20070521000006 |
News Archive
Reinforcing its reputation as a world-leading provider of automated healthcare solutions and medication adherence packaging, Omnicell UK & Ireland has launched a new generation of automated medication dispensing systems, Omnicell XT, at the forefront of technological advancement.
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
The U.S. Food and Drug Administration today approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.
In response to the current trend toward personalized medicine, the Beaumont Weight Control Center, affiliated with Beaumont Hospitals, a major Detroit-area health system, now offers individualized MicroNutrient Testing for patients.
› Verified 4 days ago
Entity Name | Mercy Clinic East Communities |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1073739041 PECOS PAC ID: 7214827922 Enrollment ID: O20070521000058 |
News Archive
Reinforcing its reputation as a world-leading provider of automated healthcare solutions and medication adherence packaging, Omnicell UK & Ireland has launched a new generation of automated medication dispensing systems, Omnicell XT, at the forefront of technological advancement.
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
The U.S. Food and Drug Administration today approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.
In response to the current trend toward personalized medicine, the Beaumont Weight Control Center, affiliated with Beaumont Hospitals, a major Detroit-area health system, now offers individualized MicroNutrient Testing for patients.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Timothy P Long, MD 901 Patients First Dr, Washington, MO 63090-4700 Ph: (636) 239-4100 | Dr Timothy P Long, MD 200 N Highway 47, Marthasville, MO 63357 Ph: (636) 433-5411 |
News Archive
Reinforcing its reputation as a world-leading provider of automated healthcare solutions and medication adherence packaging, Omnicell UK & Ireland has launched a new generation of automated medication dispensing systems, Omnicell XT, at the forefront of technological advancement.
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
The U.S. Food and Drug Administration today approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.
In response to the current trend toward personalized medicine, the Beaumont Weight Control Center, affiliated with Beaumont Hospitals, a major Detroit-area health system, now offers individualized MicroNutrient Testing for patients.
› Verified 4 days ago